Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD

队列 医学 星形胶质细胞 内科学 病理 肿瘤科 中枢神经系统
作者
Elizabeth E. Evans,Terrence L. Fisher,John E. Leonard,Alisha Reader,Vikas Mishra,Crystal Mallow,Leslie Balch,Alan Howell,Ernest Smith,Andrew Feigin,Eric Siemers,Maurice Zauderer
出处
期刊:Alzheimers & Dementia [Wiley]
卷期号:16 (S9) 被引量:7
标识
DOI:10.1002/alz.043971
摘要

Abstract Background Pepinemab (VX15/2503) is a humanized IgG4 monoclonal antibody that blocks the binding of semaphorin 4D (SEMA4D) to its plexin B1 and plexin B2 receptors. SEMA4D is upregulated in neurons and oligodendrocytes in response to stress and triggers inflammatory activation of plexin B1/B2 positive astrocytes with concomitant loss of some normal astrocyte functions. Blocking antibody to SEMA4D has been shown to reduce neurodegenerative processes in preclinical models, including Huntington’s disease (HD) and Alzheimer’s disease (AD). SIGNAL‐HD is a double‐blind, placebo‐controlled study of pepinemab in HD. Given previous studies of fluorodeoxyglucose (FDG) positron emission tomography (PET) loss in HD and the mechanism of action of pepinemab, FDG‐PET imaging was included in the SIGNAL‐HD study. Method Transgenic mouse models for HD (Q175) and AD (CVN) as well as human pathological tissue was used for immunohistochemistry. The SIGNAL‐HD study includes participants with late prodromal and early manifest HD. Results from 36 subjects in Cohort A informed group size and treatment duration in Cohort B. A subset of participants in Cohort A underwent PET scanning using FDG at baseline, at the end of the 6‐month placebo‐controlled period and at 12 months at the end of the open‐label treatment period. Result SEMA4D was upregulated and astrocyte activation was present for HD and AD based on samples from transgenic models and staged patient autopsy samples. SIGNAL‐HD Cohort A (n=36) has been completed and Cohort B (n=265) is fully enrolled. For participants in Cohort A undergoing FDG‐PET imaging (n=19), those in the pepinemab group showed increases in FDG uptake compared to baseline (median 8.6%, range: 0.5‐20.4%) while participants taking placebo showed the expected decrease after 6 months. Nominal statistical significance (p<0.05) pepinemab compared to placebo was achieved for 11/14 frontal and parietal brain regions. Conclusion Transgenic mouse models and human neuropathological analyses are consistent with an upregulation of SEMA4D in HD and AD. The increase in FDG‐PET signal in SIGNAL‐HD Cohort A suggests central target engagement and improvement in brain metabolic activity. SIGNAL‐AD, a randomized, placebo‐controlled, phase 1b/2 study of pepinemab in early AD, will also incorporate FDG‐PET and is planned to begin mid‐2020.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
脑洞疼应助糟糕的铁锤采纳,获得10
1秒前
xn201120发布了新的文献求助10
2秒前
苹果完成签到,获得积分20
2秒前
2秒前
xxttt完成签到,获得积分10
4秒前
notsoeasy发布了新的文献求助10
6秒前
一丁雨完成签到,获得积分10
6秒前
wys关闭了wys文献求助
7秒前
爱吃冬瓜发布了新的文献求助10
7秒前
xxttt发布了新的文献求助10
8秒前
情怀应助研究僧采纳,获得10
9秒前
10秒前
Hello应助ASXC采纳,获得10
12秒前
NJSGSKL发布了新的文献求助10
13秒前
14秒前
科目三应助Persist采纳,获得10
14秒前
15秒前
大模型应助xn201120采纳,获得10
15秒前
16秒前
18秒前
18秒前
小张张发布了新的文献求助30
18秒前
Tim完成签到,获得积分10
19秒前
没有蛀牙发布了新的文献求助10
19秒前
酷波er应助现代的无春采纳,获得10
20秒前
shen发布了新的文献求助10
20秒前
21秒前
21秒前
隐形曼青应助pearer采纳,获得10
21秒前
21秒前
gemn完成签到,获得积分10
22秒前
23秒前
kuokyt发布了新的文献求助10
25秒前
25秒前
25秒前
YMM发布了新的文献求助10
25秒前
汉堡包应助Ronnie采纳,获得10
26秒前
松鼠桂鱼发布了新的文献求助10
27秒前
zkk完成签到,获得积分10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976253
求助须知:如何正确求助?哪些是违规求助? 3520405
关于积分的说明 11203301
捐赠科研通 3257028
什么是DOI,文献DOI怎么找? 1798589
邀请新用户注册赠送积分活动 877755
科研通“疑难数据库(出版商)”最低求助积分说明 806521